Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
06:45pm, Tuesday, 20'th Sep 2022 Benzinga
RBC Capital Markets raised the price target on Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) from $225 to $250.
The analyst says that the company is confident that the recent APOLLO-B validates the t
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
08:00am, Monday, 19'th Sep 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 9th annual series of “RNAi Roundtabl
Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study
03:29pm, Friday, 16'th Sep 2022 Zacks Investment Research
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
These Are The Five Best And Worst Performing Large-Cap Stocks In August 2022
09:25pm, Tuesday, 13'th Sep 2022
Large companies are set to face a new set of challenges in the coming months stemming from Russia's invasion of Ukraine, rising interest rates, and the COVID-19 pandemic.
Where Alnylam Pharmaceuticals Stands With Analysts
04:24pm, Friday, 09'th Sep 2022 Benzinga
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
8
0
Analyst Ratings for Alnylam Pharmaceuticals
01:33pm, Friday, 09'th Sep 2022 Benzinga
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?
12:39pm, Friday, 09'th Sep 2022 Zacks Investment Research
Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?
09:47am, Friday, 09'th Sep 2022
Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
Want to Beat Alphabet Stock? Buy These 2 Winners of the Bear Market
02:45pm, Sunday, 04'th Sep 2022 The Motley Fool
They're both soaring thanks to a handful of recent catalysts.
Want to Beat Alphabet Stock? Buy These 2 Winners of the Bear Market
10:45am, Sunday, 04'th Sep 2022
They're both soaring thanks to a handful of recent catalysts.
Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?
03:30pm, Wednesday, 31'st Aug 2022 Zacks Investment Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
08:00am, Monday, 29'th Aug 2022
Biotech stocks are scorching right now. But the best of the best have strong gains.
Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why
05:35pm, Friday, 26'th Aug 2022 Zacks Investment Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.
Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why
03:03pm, Friday, 26'th Aug 2022
Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.
Can Intellia One-Up Alnylam In Transthyretin Amyloidosis?
04:28pm, Tuesday, 23'rd Aug 2022
Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR.
